Search Results
Jun 04, 2026, 22:45 ET WuXi Biologics Singapore CRDMO Hub Completes Modular Topping-Out of Drug Product Facility
Singapore's position as a leading biopharmaceutical hub. On this site, WuXi Biologics' subsidiary WuXi XDC achieved mechanical completion of its Singapore ADC production site in 2025.Spanning approximately 30,000 square meters, the modular DP facility will feature advanced manufacturing lines, centralized
More news about: WuXi Biologics
Jun 04, 2026, 08:30 ET Stronger Together, Shaping the Future | WuXi XDC and BioDlink Successfully Concluded 2026 Open Day
following the strategic integration.The event brought together biotech customers, industry leaders and innovators to explore how an integrated ADC/XDC CRDMO platform can accelerate the development and commercialization of next-generation bioconjugate therapies.SUZHOU,
More news about: BioDlink Biopharm Co., Ltd.
Jun 04, 2026, 04:35 ET World's First CLDN18.2 ADC for Regulatory Review: Innovent Biologics Announces IBI343 (arcotatug tavatecan) Met Primary Endpoint in International Phase 3 Study in Advanced Refractory Gastric Cancer and NDA Accepted by China NMPA
is a recombinant human anti-CLDN18.2 monoclonal antibody-drug conjugate (ADC) developed by Innovent Biologics. It specifically binds to the tumor cells expressing CLDN18.2, triggering CLDN18.2-dependent internalization of the ADC. Once inside the cell, the cytotoxic payload is released, resulting in DNA
More news about: Innovent Biologics
Jun 03, 2026, 16:05 ET ADC Therapeutics Announces Results From LOTIS-5 Phase 3 Confirmatory Clinical Trial of ZYNLONTA® in Combination with Rituximab in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
therapy.About ADC Therapeutics ADC Therapeutics (NYSE: ADCT) is a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), transforming treatment for patients through our focused portfolio with ZYNLONTA® (loncastuximab tesirine-lpyl).ADC Therapeutics'
More news about: ADC Therapeutics SA
Jun 03, 2026, 03:00 ET Ingenix Raises €13m From Sofinnova Partners-Led Syndicate to Scale Modality Fusion, a Novel Architecture for Drug Development
compounds. We're thrilled to back a team that gets that."The Engine in Action: ADC Payload PrioritizationIn a recent engagement, Ingenix applied its Biological Reasoning Engine to a dual-payload ADC prioritization problem for an oncology biotech which had thousands of possible payload
More news about: Ingenix
Jun 03, 2026, 00:00 ET Antengene to Present First Preclinical Data on ATG-207 (αCD3-TGF-β Bifunctional Fusion Protein) at EULAR 2026
preclinical to commercial stages, with key investigational candidates including ATG-022 (CLDN18.2 ADC), ATG-037 (oral CD73 inhibitor), ATG-101 (PD-L1 x 4-1BB bispecific antibody), ATG-125 (B7-H3 × PD-L1 bispecific ADC), ATG-207 (αCD3-TGF-β bifunctional fusion protein), as well as T cell engager (TCE) programs
More news about: Antengene Corporation Limited
Jun 02, 2026, 20:00 ET Kelun-Biotech Presents First-in-human Study Data for Its Novel B7-H3 ADC SKB500 at ASCO 2026
in the clinical stage. Kelun-Biotech has established one of the world's leading proprietary ADC and novel DC platforms, OptiDC™, and has 2 ADC projects with 5 indications approved for marketing, and multiple ADC and novel DC assets in clinical or preclinical research stage. For more information, please
More news about: Kelun-Biotech
Jun 02, 2026, 20:00 ET 2026 ASCO | 科倫博泰創新B7-H3 ADC SKB500首次人體研究數據公布
2026年6月3日 /美通社/ -- 2026年6月3日，四川科倫博泰生物醫藥股份有限公司(「科倫博泰」或「公司」，6990.HK)宣布，在美國芝加哥舉行的2026年美國臨床腫瘤學會(ASCO)年會上，吉林省腫瘤醫院劉海峰教授以快速口頭報告的形式公布了創新B7-H3 ADC SKB500治療晚期實體瘤的首次人體研究結果(摘要編號#3011 |分子靶向藥物與腫瘤生物學)。SKB500采用了高親和力、高親水性及內吞作用更強的抗體，並在抗體恆定區進行了沉默Fc效應功能的工程改造。此外，其抗體通過可裂解的親水性AAA連接子與具有中等毒性的載荷連接，藥物抗體比(
More news about: 科倫博泰
Jun 02, 2026, 11:32 ET MT Group Surpasses 5,000 Customized Biospecimen Collections, Reinforcing Its Position as a Leading Specialty CRO for Prospective Human Tissue and Blood Procurement
validating early-detection assays, baseline biomarker discovery programs, and pre-treatment cohorts in immuno-oncology and antibody-drug conjugate (ADC) target validation. Pathologist-reviewed quality control includes tumor content estimation, necrosis assessment, fixative confirmation, and morphology
More news about: MT Group
Jun 02, 2026, 10:05 ET CREATV BIO AND NEOVIA ONCOLOGY ANNOUNCE STRATEGIC PARTNERSHIP TO STUDY MULTIPLE DRUG RESISTANCE (MDR) IN SOLID TUMORS
therapy, Neovia is also evaluating the broader platform potential of NEV-801 in next-generation oncology applications, including antibody-drug conjugate (ADC) strategies."We selected Creatv Bio because of their strong scientific capabilities and extensive experience supporting biomarker research across
More news about: Creatv MicroTech, Inc.
Jun 01, 2026, 09:24 ET Promising Phase 1 Data for Servier's Emiltatug Ledadotin (Emi-Le) in Adenoid Cystic Carcinoma (ACC) Presented at ASCO 2026
June 1, 2026 /PRNewswire/ -- Servier today announced promising new Phase 1 clinical data for Emi-Le, an investigational antibody drug conjugate (ADC) directed against B7-H4, during an oral session at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting in Chicago, Illinois.
More news about: Servier Pharmaceuticals
Jun 01, 2026, 08:31 ET The Evolving EGFR NSCLC Market: 8 Emerging Late-stage Therapies to Watch | DelveInsight
several late-stage ADC candidates are advancing through pivotal studies, including izalontamab brengitecan from Bristol Myers Squibb, telisotuzumab adizutecan from AbbVie, and sacituzumab tirumotecan from Merck. These programs highlight the growing industry focus on ADC innovation within
More news about: DelveInsight Business Research, LLP
Jun 01, 2026, 03:23 ET Godawan Artisanal Single Malt Celebrates 125 Global Awards, Taking Rajasthan's Story of Craft and Conservation to the World
environments today stands as a globally recognised Indian single malt. Across prestigious international platforms, including Monde Selection, Clio Awards, ADC Awards, One Club, Spikes Asia, and the International Taste Institute, Godawan has been honored for its liquid, packaging, illustration, design,
More news about: Diageo India
Jun 01, 2026, 01:51 ET Hengrui Pharma Presents More Than 90 Oncology Studies at ASCO 2026, Highlighting Progress Across Multiple Tumor Types
noninferior to standard TCHP, offering a new treatment option for patients who cannot tolerate severe hematologic toxicity.Gastrointestinal Cancers: ADC and Immunotherapy Combination Treatments Show PromiseIn the field of colorectal cancer, the HORIZON-CRC01 study led by Professor Jin Li of
More news about: Hengrui Pharma
Jun 01, 2026, 00:00 ET Minghui Pharmaceutical and Qilu Pharmaceutical Co-Announces Updated Clinical Data of MHB088C (QLC5508) from Phase I/II study in Heavily Pretreated mCRPC Patients at 2026 ASCO Annual Meeting
Phase III trials for thyroid eye disease; a novel PD-1/VEGF bispecific antibody in Phase 2 trials, being evaluated in combination with a TROP2 ADC; and a B7-H3 ADC in Phase 3 trial for 2L SCLC —both ADCs with strong best-in-class potential.Forward-Looking StatementsThis press release
More news about: Minghui Pharmaceutical
May 31, 2026, 09:00 ET HARMONi-6 Demonstrates Significant Overall Survival Benefit (HR=0.66): Ivonescimab Plus Chemotherapy Superior to PD-1 Plus Chemotherapy in First-Line sq-NSCLC Landmark Results to Be Presented at ASCO 2026 Plenary Session
immunotherapy: 13.9% in the treatment group vs 19.2% in the control group; proportions receiving targeted therapy: 12.4% vs 17.3%; proportions receiving ADC therapy: 4.5% vs 5.6%; proportions participating in other clinical trials: 0.8% vs 2.3%.Favorable safety profile comparable to tislelizumab
More news about: Akeso, Inc.
May 30, 2026, 20:00 ET Sacituzumab Tirumotecan (sac-TMT) in Combination with Pembrolizumab for First-Line Treatment of PD-L1-Positive NSCLC Published in The Lancet
projects are in the clinical stage. Kelun-Biotech has established one of the world's leading proprietary ADC and novel DC platforms, OptiDC™, and has 2 ADC projects approved for marketing, and multiple ADC and novel DC assets in clinical or preclinical research stage. For more information, please visit
More news about: Kelun-Biotech
May 30, 2026, 20:00 ET 榮登《柳葉刀》主刊！蘆康沙妥珠單抗(sac-TMT)聯合帕博利珠單抗一線治療 PD-L1 陽性 NSCLC III期重磅結果發表
HR值分別為0.28和0.44；同時已觀察到總生存期(OS)的積極獲益趨勢，HR為0.55。蘆康沙妥珠單抗(sac-TMT)聯合組整體安全性可控，聯合治療與蘆康沙妥珠單抗(sac-TMT)單藥或帕博利珠單抗單藥已建立的安全性特征一致，未發現新的安全性信號。這是首個ADC聯合免疫檢查點抑制劑在NSCLC一線治療中達到主要終點的III期臨床研究，首次證明了「ADC+IO」方案(sac-TMT聯合帕博利珠單抗)作為NSCLC一線治療具有實現生存獲益的潛力。該成果問鼎《柳葉刀》主刊，表明這一療法的臨床價值與學術價值已獲得國際權威認可。關於蘆康沙妥珠單抗(sac-TMT)(佳泰萊®)作為公司的核心產品，蘆康沙妥珠單抗(sac-TMT)是一款公司擁有自主知識產權的新型TROP2
More news about: 科倫博泰
May 30, 2026, 14:30 ET Whitehawk Therapeutics Presents Real‑World Analysis Confirming SEZ6 as a Highly Expressed, Clinically Relevant Target for SCLC and Other Neuroendocrine Tumors at ASCO 2026
and emerging ADC targets in SCLC SEZ6 expression is positively correlated with DLL3 expression across neuroendocrine carcinomas, indicating potential for combination Findings support Whitehawk's development of SEZ6-directed ADC, HWK-206, with
More news about: Whitehawk Therapeutics, Inc.
May 30, 2026, 00:30 ET 2026 ASCO | 蘆康沙妥珠單抗(sac-TMT) III期OptiTROP-Lung05研究成果於ASCO口頭報告和《柳葉刀》同步發佈
全國牽頭主要研究者、同濟大學附屬東方醫院周彩存教授表示：「OptiTROP-Lung05研究取得的積極結果令人振奮。不僅為蘆康沙妥珠單抗在肺癌治療中的『應用前移』提供了循證證據，更率先驗證了『ADC+IO』協同策略在PD-L1陽性晚期NSCLC一線治療中的可行性，有望為廣大肺癌患者帶來全新的生存希望。」
More news about: 科倫博泰
May 29, 2026, 23:32 ET The Results of Phase III OptiTROP-Lung05 Study of Sacituzumab Tirumotecan (sac-TMT) Presented as an ASCO Oral Presentation and Simultaneously Published in The Lancet
in the clinical stage. Kelun-Biotech has established one of the world's leading proprietary ADC and novel DC platforms, OptiDC™, and has 2 ADC projects with 5 indications approved for marketing, and multiple ADC and novel DC assets in clinical or preclinical research stage. For more information, please
More news about: Kelun-Biotech
May 29, 2026, 23:29 ET Kelun-Biotech Presents Pivotal Phase II Data for Lunbotinib Fumarate (A400/EP0031) in RET Fusion-Positive NSCLC at 2026 ASCO
in the clinical stage. Kelun-Biotech has established one of the world's leading proprietary ADC and novel DC platforms, OptiDC™, and has 2 ADC projects with 5 indications approved for marketing, and multiple ADC and novel DC assets in clinical or preclinical research stage. For more information, please
More news about: Kelun-Biotech
May 28, 2026, 16:05 ET Whitehawk Therapeutics to Present at the Jefferies 2026 Global Healthcare Conference
clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug conjugate (ADC) cancer treatments, today announced Dave Lennon, PhD, President and CEO, will present at the Jefferies 2026 Global Healthcare Conference in New York
More news about: Whitehawk Therapeutics, Inc.
May 28, 2026, 08:54 ET Florida Cancer Specialists & Research Institute Advances the Future of Cancer Care
open-label, phase 3 study of ZL-1310, a DLL3 antibody-drug conjugate (ADC), compared to investigator's choice therapy in participants with relapsed small cell lung cancer (DLLEVATE).BNT326-01: A Phase 1b/2 trial of BNT326/YL202 (HER3 ADC) as monotherapy and in combination with pumitamig (anti-PD-L1
More news about: Florida Cancer Specialists & Research Institute
May 28, 2026, 02:06 ET Leads Biolabs' PD-L1/4-1BB Bispecific Antibody Selected for Oral Presentation at WCLC 2026, Demonstrating Sustained Breakthrough Efficacy Signals in NSCLC
proprietary technology platforms, including LeadsBody platform (a CD3 T-cell engager platform), X-body platform (a 4-1BB engager platform), TOPiKinectics (ADC platform) and ImBiTDC (TDC Platform), which serve as the cornerstone for our continued innovation and have been validated by the clinical outcomes of
More news about: Nanjing Leads Biolabs Co., Ltd.